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Abstract 
Early detection of Alzheimer’s disease (AD) will help researchers to better understand the 
disease and develop improved treatments. Recent developments have thus focused on 
identifying biomarkers for mild cognitive impairment due to AD (MCI) and AD during the 
preclinical phase. The aim of this pilot study is to determine whether exhaled volatile organic 
compounds (VOCs) can be used as a non-invasive method to distinguish controls from MCI, 
controls from AD and to determine whether there are differences between MCI and AD. The 
study used gas chromatography – ion mobility spectrometry (GC-IMS) techniques. 
Confounding factors, such as age, smoking habits, gender and alcohol consumption are 
investigated to demonstrate the efficacy of results. One hundred subjects were recruited 
including 50 controls, 25 AD and 25 MCI patients. The subject cohort was age- and gender-
matched to minimise bias. Breath samples were analysed using a commercial GC-IMS 
instrument (G.A.S. BreathSpec, Dortmund, Germany). Data analysis indicates that the GC-IMS 
signal was consistently able to separate between diagnostic groups [AUC±95%, sensitivity, 
specificity], controls vs MCI: [0.77 (0.64 – 0.90), 0.68, 0.80], controls vs AD: [0.83 (0.72 – 0.94), 
0.60, 0.96], and MCI vs AD: [0.70 (0.55 – 0.85), 0.60, 0.84]. VOC analysis indicates that six 
compounds play a crucial role in distinguishing between diagnostic groups. Analysis of 
possible confounding factors indicate that gender, age, smoking habits and alcohol 
consumption have insignificant influence on breath content. This pilot study confirms the 
utility of exhaled breath analysis to distinguish between AD, MCI and control subjects. Thus, 
GC-IMS offers great potential as a non-invasive, high-throughput, diagnostic technique for 
diagnosing and potentially monitoring AD in a clinical setting. 
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1 Introduction 
The increasing lifespan of the human population is inevitably leading to a growing prevalence 
of neurodegenerative diseases (NDDs). Alzheimer’s disease (AD) is a degenerative brain 
disorder and is the most common cause of dementia [1]. Dementia is characterised by a 
decline in memory, language, problem-solving, planning, reasoning, and other basic cognitive 
abilities, which has a direct impact on performing everyday activities [2]. The decline occurs 
because nerve cells (neurons), in parts of the brain involved in cognitive functions, have been 
damaged or destroyed [2]. While there is currently no cure or way to stop or slow disease 
progression, medication, support and care can help manage symptoms and improve quality 
of life. In 2017, the worldwide dementia prevalence was estimated at 50 million people [3], 
with a global societal cost of $1 trillion [4] resulting from direct (medical and social care) and 
indirect (unpaid caregiving by families and friends) costs. The economic impact and costs have 
been estimated to be greater than that of common chronic diseases, such as heart disease 
and cancer [5]. Progression of AD can be categorised into three phases: preclinical, mild 
cognitive impairment (MCI) and clinical phases [6]. The preclinical phase does not include 
noticeable clinical signs; however, there are gradual physiological changes at the cellular level 
associated with disease pathogenesis [7]. MCI is used in this research to describe Mild 
Cognitive Impairment due to Alzheimer’s disease. This is a transitory phase in the progression 
of AD from a preclinical illness to symptomatic AD, which then progresses to a dementia 
where there is impairment in more than one domain of cognitive function and activities of 
daily living, such as getting dressed and doing household activities. In this study, we use the 
term Alzheimer’s disease (AD) to describe this progression from MCI to more than one 
domain of cognitive function and then to dementia where activities of daily living are 
becoming impaired. The assessment of MCI remains clinical, taking a history, checking 
dementia screening bloods, a brain scan (either CT or MRI scan) and using neuropsychology 
testing (e.g. using MoCA, ACE-III and M-ACE sub-score) to come to a clinical diagnosis. In 
research centres, biomarkers such as cerebrospinal fluid (CSF) testing and amyloid PET scans 
are used to confirm a biomarker diagnosis for MCI due to AD using NIA-AA criteria [8,9]. It is 
widely accepted that early detection of AD (ideally, in the preclinical phase) will be key to 
preventing, slowing and stopping the disease [2]. This is when disease modifying treatments 
will be most effective. Some research has suggested that the first AD-related brain changes 
may begin more than 20 years before clinical symptoms emerge [10]. Identifying biomarkers 
that can reliably identify AD-related developments at an early stage would have a high clinical 
value, as it could enable early preventative treatments. Blood-based biomarkers, such as 
amyloid-β markers [11], could provide minimally-invasive methods. However exhaled breath 
has shown potential as a non-invasive diagnostic tool. This involves the analysis of exhaled 
volatile organic compounds (VOCs). There is an estimate of over 3,000 VOCs in human breath, 
which are a combination of by-products of normal metabolic activity and, in some cases, 
specific biomarkers associated with a disease [12–15]. Exhaled breath analysis has the 
potential to have a significant impact on enhancing the diagnosis and monitoring of AD, since 
the approach is non-invasive, relatively cost-effective and potentially straight-forward to 
implement [7]. A recent review paper by Subramaniam et al. [7] explored the emergence of 
breath testing as a non-invasive diagnostic modality for NDDs. Early work by Stüwe et al. 
[16,17] used breath tests to investigate hepatic mitochondrial dysfunction for Friedreich 
ataxia and Huntington’s disease. These studies utilised isotope-selective nondispersive 
infrared spectrometry (IRIS) for evaluation of methyl 13C-methionine. In addition to this, 
there have been at least four breath-based studies investigating the efficacy of diagnosing 
AD. These studies used gas chromatography–mass spectrometry (GC-MS) [18,19], Cyranose 
320 electronic nose (eNose) [20], ion mobility spectro-scopy (IMS) [20] and custom-built 
sensor systems [18,19,21]. Three out of four of these studies investigated AD, as well as 
Parkinson's disease (PD), against control subjects. To the best of our knowledge, this breath 
study is the first to investigate MCI, AD and controls using a GC-IMS (gas chromatography–
ion mobility spectrometer) technique. The aim of this pilot study is to determine whether 
exhaled VOCs can be used to distinguish controls from MCI, controls from AD, and MCI from 
AD inbreath. Confounding factors, such as age, smoking habits, gender and alcohol 
consumption are investigated to demonstrate the efficacy of results. 
 
2 Materials and methods 
2.1 Subjects 
A total of 100 subjects were recruited for this case-control study. Ethical approval was 
obtained from local research ethics committee (Ref No.17/18-829, University of Plymouth, 
UK). MCI and AD patients were recruited by Re:Cognition Health (Plymouth, UK), along with 
their respective partners as control subjects. The control subjects were clinically defined as 
non-MCI and AD sufferers. The volunteers and patients received information sheets and were 
consented following a face-to-face interview by a medical doctor. The study cohort includes 
50 patients (25 MCI, 25 AD) and 50 controls. MCI patients were recruited based on the 
investigator’s assessment (Author S.P.), who reviewed their clinical history and confirmed 
that the subject demonstrated amnestic symptoms highly suggestive of AD. AD subjects were 
recruited based on M-ACE scores [22] below 23, a clinical assessment of the presence of 
amnestic problems, and another domain of cognitive problems, including patients with 
dementia who had functional impairment. Controls included subjects that had no-known 
history of neurological disorders (self-reported). The mean age of the MCI and AD group was 
74.9 (standard deviation: 7.6), including 29 males and 21 females. An overview of the 
demographic data of MCI, AD and control subjects is shown in Table 1. 
Table 1. Demographic data of controls subjects and MCI and AD patients 
Parameter MCI (n=25) AD (n=25) Controls (n=50) 
Mean age (SD) 72.2 (7.3) 77.5 (7.2) 71.2 (7.3) 
Gender ratio M:F 15:10 14:11 17:33 
Smoking habits 16 ex-smokers 9 never smokers 
10 never smokers 
12 ex-smokers 
3 current smokers 
22 never smokers 
25 ex-smokers 
3 current smokers 
Alcohol – mean units/week 
(SD) 10.8 (11.6) 3.5 (6.4) 11.3 (13.4) 
Medication 
(No. of Subjects) 
Omeprazole (8) 
Atorvastatin (6) 
Bisoprolol (5) 
Paracetamol (4) 
Simvastatin (4) 
Amlodipine (3) 
Warfarin (3) 
Aspirin (3) 
Citalopram (3) 
64 others (<=2) 
Donepezil (10) 
Atorvastatin (6) 
Omeprazole (4) 
Aspirin (4) 
Amlodipine (4) 
Folic Acid (4) 
Clopidogrel (3) 
Citalopram (3) 
47 others (<=3) 
Not available (N/A) 
Co-diseases / conditions 
(No. of Subjects) 
Hypertension (11) 
Depression (6) 
High Cholesterol (6) 
Atrial Fibrillation (4) 
Hiatus Hernia (3) 
Migraines (3) 
Diabetes Mellitus (3) 
58 others (<=2) 
Hypertension (7) 
High Cholesterol (5) 
Gastric Reflux (4) 
54 others (<=2) 
Not available (N/A) 
 
2.2 Breath analysis platform 
This study utilised GC-IMS technology as an analytical platform. In recent years, there has 
been a growing presence of portable GC-IMS analysers, which have demonstrated capabilities 
in medical diagnostics [23,24]. The BreathSpec (G.A.S., Dortmund, Germany) used in this 
study, is a commercial instrument, consisting of a gas chromatograph (GC) and an ion mobility 
spectrometer (IMS). Importantly, the unit analyses at point of care, only takes a few minutes 
to undertake an analysis and is patient friendly, with breath samples collected without putting 
strain on the subject. The BreathSpec is equipped with a MXT-200 mid-polarity column 
(Thames Restek, Saunderton, UK) for gas chromatographic separation, based on chemical 
interactions with the column. This stage is followed by a drift tube IMS detector, whereby 
analytes are ionised and injected into a drift tube, using a shutter grid. The ions drift against 
a buffer gas under influence of a uniform electric field (400 V/cm), where the various ions 
achieve different velocities, inversely related to their size, mass and charge [25]. The ions are 
then collected on a Faraday plate, to produce a time-dependent signal that corresponds with 
ion mobility. This technique can measure substances in the low parts-per-billion (ppb) range 
and delivers measurement results in 10 minutes. This unit is fitted with a circulator gas flow 
unit (CGFU), which recirculates and filters ambient air. This allows the unit to operate without 
the need of an external gas supply (e.g. nitrogen generator). The buffer gas flow rate was 150 
ml/min and carrier flow rate through the instrument was 15 ml/min, while the sample was 
being introduced. The carrier flow rate was then ramped to 50ml/min over the10-minute 
measurement time. The temperatures of the GC column, IMS and sample loop were set to 
45°C. 
 
2.3 Breath sampling 
The sampling procedure requires only four seconds of exhaled breath [26]. Subjects were 
provided with a disposable plastic mouthpiece, which pushes into the mouthpiece 
holder/sample inlet and connects directly to the front-panel of the instrument. The 
mouthpieces are open-ended, which allows air inside the mouthpiece to be displaced as 
exhalation proceeds. As a result, the sampling system can separate out the last portion of 
exhaled breath –known as end-tidal breath. This refers to the last portion (350 mL) of exhaled 
breath, expelled from within the lungs and the lower-airways, which have undergone gaseous 
exchange with the blood in the alveoli [27]. Users do not need to exhale until their lungs are 
as empty as possible and instead are simply asked to breathe normally. This improves 
reproducibility and makes the device suitable for vulnerable subjects, such as the elderly. A 
typical GC-IMS output response to a breath sample (control subject from this study), is shown 
in Figure 1. The obtained sample is represented in a 3D topographic map, whereby each point 
is characterised by the retention time in the chromatographic column (in seconds), the drift 
time (in milliseconds) and the intensity of ion current signal (in volts). The signal intensity is 
indicated by colour, where each high-intensity area represents a single or combination of 
chemicals (with the same properties). The long red line is the reactant ion peak (RIP), which 
is a background signal present all the time. Laboratory Analytical Viewer (LAV) software 
(v2.2.1, G.A.S., Dortmund, Germany) was used for GC-IMS signal viewing. 
 
 
Figure 1. GC-IMS output example 
 
2.4 Data analysis 
Our data analysis approach focuses on distinguishing between the three diagnostic groups: 
AD, MCI and controls. However, since there are more controls than MCI or AD subjects, the 
effect of imbalanced datasets needs to be considered [28]. For this reason, a random selection 
of 25 controls were used for this analysis. The first step of data analysis involves a pre-
processing stage. The aim of this is to reduce the dimensionality, thus leaving data that is non-
background. A typical GC-IMS dataset contains 11 million data points, which has high 
dimensionality, but low information content. The area of interest is defined as a region on the 
GC-IMS output associated with the VOC ‘fingerprint’ of a subject, i.e. the VOC peak signals. 
These signals are located near each other in the output file and thus we are able to crop this 
section of the data. The size of the cropped area is selected by visualisation of the data and 
ensuring that it can be applied across all samples, without losing any chemical information. 
The next step involves thresholding. Since we are only interested in the VOC peaks, the spaces 
between the peaks (i.e. background) is removed using a static threshold. These steps reduce 
the number of data points by a factor of 100. Following this, a supervised feature selection 
procedure is undertaken, with class prediction performed using a k-fold cross-validation 
method (where k=10 in our case). This method involves partitioning the original data set into 
10 equally sized subsets. Of the 10subsets, a single subset is retained as the validation data 
for testing the model and remaining nine subsets are used as training data. Training features 
are identified using Wilcoxon rank-sum test between the two groups and those feature points 
with the lowest p-value selected and used to construct models based on five different 
classifiers. These features are identified purely on a statistical basis and not on any biological 
function at this stage. This analysis was run using R (version 3.6.0) with standard machine 
learning sub-packages: support vector machine (SVM) – kernlab; sparse logistic regression 
(SLR) – glmnet; Gaussian process – gbm, neural network –neuralnet, and random forest (RF) 
– randomForest. This process is repeated 10 times (number of folds), with each subset used 
once as validation data. The10 results are then combined to produce a single estimation and 
from this, statistical parameters calculated. In addition to the classification analysis, it is 
possible to identify unknown VOCs that relate significantly to the efficacy of the generated 
results. Using GC-IMS Library Search software (v1.0.1, G.A.S., Dortmund, Germany), we can 
potentially identify compounds based on gas chromatographic retention times and ion 
mobility drift times, by referencing a NIST database with around 83,000 compound entries 
[29]. Here, we can plot the identified features back onto the original GC-IMS output and then 
tentatively identify those chemicals. The instrument was normalised to match the GC-IMS 
Library Search software with the equipped column using a standard ketone mix (2-
butanone,2-pentanone, 2-hexanone, 2-heptanone, and 2-octanone). 
 
2.5 Confounding factors 
Applications of exhaled breath analysis for diagnostic and/or monitoring purposes should 
consider possible confounding factors [30]. These are factors which are known to have some 
impact on breath content and can thus introduce bias or generate spurious associations. For 
example, age is a critical confounder in this study, because increased age is the biggest risk 
factor for AD. In addition to age, smoking habits, gender and alcohol consumption were 
considered. The impact of these factors can be evaluated by re-running the classification 
analysis applied to the diagnostic groups, after re-organising the patients and volunteers 
based on confounding factors. To simplify the analysis and create more evenly-balanced 
groups, the confounding groups were defined as: Age [>75 vs <=74 years], smoking habits 
[never smokers vs ex/current smokers], gender [male vs female] and alcohol consumption 
[>=11vs <11 units/week]. While the UK guidelines for regular alcohol consumption state that 
people should consume no more than 14 units of per week [31], men and women over 65 are 
generally advised to have no more than 11 units per week [32]. Thus, the latter threshold has 
been used for our confounding factor analysis. The confounding factor groups are 
summarised in Table 2. 
 
 
Table 2. Summary of confounding factor groups 
Factor Group MCI AD Control Total 
Age <= 74 years 15 8 34 57 > 75 years 10 17 16 43 
Smoking Ex/current smokers 16 15 28 59 Never smokers 9 10 22 41 
Gender Male 15 14 17 46 Female 10 11 33 54 
Alcohol < 11 units per week 22 14 31 67 >= 11 units per week 3 11 19 33 
 
3 Results 
Analysis results are presented in Figure 2 as overlapping receiver operating characteristic 
(ROC) curves. The corresponding area under curve (AUC) is a measure of how well parameters 
can distinguish between diagnostic groups, i.e. MCI, AD and controls. We have also calculated 
NPV (negative predictive value) and PPV (positive predictive value) for the different 
comparisons. Analysis results for diagnostic groups were achieved using SLR and are shown 
in Table 3.  
 
 
 
Figure 2. Diagnostic group analysis results: Controls vs MCI (blue); Controls vs AD (black); MCI vs AD (red). 
 
 
Table 3. GC-IMS diagnostic group results 
Test AUC ± 95% Sensitivity Specificity PPV NPV P-value 
Controls vs MCI 0.77 (0.64 – 0.90) 0.68 (0.46 – 0.85) 0.80 (0.59 – 0.93) 0.77 0.71 0.0004 
Controls vs AD 0.83 (0.72 – 0.94) 0.60 (0.39 – 0.79) 0.96 (0.80 – 1.00) 0.94 0.71 0.0001 
MCI vs AD 0.70 (0.55 – 0.85) 0.60 (0.39 – 0.79) 0.84 (0.64 – 0.95) 0.79 0.68 0.0076 
 
3.1 Chemical identification 
VOC analysis indicates that three compounds, tentatively identified as acetone, 2-propanol 
and 2-butanone play a crucial role in distinguishing between controls and AD subjects. In the 
test for AD vs MCI, changes in2-propanol, hexanal and 1-butanol were significant. The 
separation of controls and MCI relied on changes observed in 2-propanol, hexanal and 
heptanal. 
 
3.2 Confounding factor 
The analysis previously conducted on the AD, MCI and control groups was repeated, using the 
same analytical techniques and algorithms, on the confounding factor groups of age, smoking 
habits, gender and alcohol consumption. The analysis results are summarized in Table 4. 
 
Table 4. GC-IMS confounding factors results 
Test AUC ± 95% Sensitivity Specificity PPV NPV P-value 
Age 
[>75 vs <=74 years] 
0.55 (0.43 – 0.67) 0.70 (0.54 – 0.83) 0.47 (0.34 – 0.61) 0.50 0.68 0.8070 
Alcohol 
[>=11 vs <11 units/week] 
0.60 (0.48 – 0.72) 0.58 (0.46 – 0.70) 0.70 (0.51 – 0.84) 0.80 0.45 0.0492 
Gender 
[Male vs Female] 
0.54 (0.42 – 0.65) 0.70 (0.54 – 0.82) 0.46 (0.33 – 0.60) 0.52 0.64 0.2668 
Smoking 
[Ex/current vs Never] 
0.56 (0.44 – 0.68) 0.81 (0.69 – 0.90) 0.39 (0.24 – 0.55) 0.66 0.59 0.1515 
 
 
Table 4 demonstrates that the possible confounding factors of gender, smoking and age have 
insignificant influence on breath content. Alcohol consumption seems to have the most 
influence on breath, with an AUC of 0.60. 
 
4 Discussion 
While the exact mechanisms related to AD pathogenesis are not fully understood, there is 
some evidence to suggest that defects in mitochondrial metabolism (i.e. changes in 
mitochondrial function and potential dysfunction) play a key role in neurodegeneration [33–
35]. Furthermore, that mitochondrial dysfunctions in NDDs are associated with increased 
production of reactive oxygen species (ROS), which cause cell damage and intercellular 
oxidative stress [36]. Endogenous VOCs (produced in the body) follow metabolic pathways 
and are transported via the bloodstream to the lungs, where they are exhaled in breath [37]. 
Oxidative stress has been detected in blood [38]and thus presents an opportunity for the 
application of breath analysis to facilitate the discovery and evaluation of biomarkers 
associated with cellular energy metabolism, mitochondrial dysfunction and oxidative stress 
[7]. In recent years, there have been four original research articles published, investigating 
the efficacy of breath-based methods for the diagnosis AD [7]. Tisch et al. [18] were the first 
to test the efficacy of breath testing for the detection of AD and PD. This study included 57 
subjects (15 AD, 30 PD, 12controls) and utilised gas chromatography–mass spectrometry (GC-
MS) and nanomaterial-based sensors as analytical platforms. The GC-MS comparison 
between AD patients and controls yielded 24 substances that occurred insignificantly 
different concentrations and the nanomaterial-based sensor analysis was able to distinguish 
between AD and controls with a classification accuracy of 85% (sensitivity 93%, specificity 
75%). Bach et al. [20] used the Cyranose 320 eNose and ion mobility spectrometry (IMS) to 
detect exhaled breath patterns of AD, PD and controls (18 AD, 16 PD and 19 controls). Results 
from the eNose were able to somewhat discriminate between groups (sensitivity 76.2%, 
specificity 45.8%, p-value 0.025). The associated linear discriminant analysis (LDA) model was 
fitted to a dataset from another site; however, it was not able to detect AD patients 
(sensitivity 56.6%, specificity 49.1, p-value 0.658). The analysis using IMS detected significant 
differences in five VOCs and utilised a decision tree of four variables, including 1-butanol and 
2-methylfuran, to show an accuracy of 94% when differentiating patients with AD from 
controls, i.e. 3 out of 52 AD patients being misclassified. The key disadvantage of using the 
decision tree approach is that the individual analytes are not suitable to differentiate patients 
with AD and PD from HC; instead, it is a combination and sequence of analytes that make 
prediction possible. Lau et al. [19] used a custom-built exhaled breath sensors system and GC-
MS to evaluate the breath of 60 subjects (20 AD, 20 PD and 20 controls). GC-MS results 
showed that four VOCs were consistently present in all patient and control groups. Cluster 
analysis of the eNose results were able to distinguish between AD, PD and controls. 
Mazzatenta et al. [21] used an iAQ-2000 sensor system to investigate the breath of 15 AD and 
44 controls. The breath frequency of AD patients was increased, compared to the control 
cohort, but associated with a reduced amplitude. Moreover, the average amount of VOCs in 
AD patients was less, compared with controls. VOC fingerprint analysis was conducted using 
clustered VOCs, generated using their relative abundances. These were observed to differ 
significantly between exhaled AD breath samples and controls; however, the results were not 
quantified using AUC, sensitivity, specificity, etc. Exhaled breath study demographics from 
previous AD studies (and this study) are summarised in Table 5.  
 
Table 5. Summary of AD-related exhaled breath study demographics. 
Authors Group 
Average age ± SD  
(age range) 
Male:Female ratio N = 
Mazzatenta et al. 
[21] 
AD n/a ± n/a (55-95) n/a 15 
Control n/a ± n/a (19-105) n/a 44 
Lau et al. [19] 
AD 74.9 ± 7.5 (n/a) 6:14 20 
Control 67.6 ± 7.0 (n/a) 5:15 20 
Bach et al. [20] 
AD 71.5 ± 8.7 (n/a) 17:22 39 
Control 63.2 ± 11.0 (n/a) 16:19 35 
Tisch et al. [18] 
AD 68 ± 10 (51-81) 7:8 15 
Control 61 ± 7 (51-73) 5:7 12 
Tiele et al. 
MCI 72.2 ± 7.3 (59-86) 15:10 25 
AD 77.5 ± 7.2 (62-90) 14:11 25 
Control 71.2 ± 7.3 (60-87) 17:33 50 
 
The key advantage of our study is that the ages and genders of the subject cohort are 
approximately balanced. Furthermore, by recruiting MCI and AD patients with their 
respective partners as controls, it is possible to design a more robust experiment and 
minimise the possible effects of lifestyle and environmental factors, which can potentially 
introduce significant inter-personal differences [30]. Moreover, age-matching is a critical 
factor to consider, since more women than men have AD and other forms of dementia [2]. 
For example, almost two-thirds of Americans with Alzheimer’s are women [39]. It has been 
suggested that this discrepancy is due to women generally living longer than men, which 
increases the risk factor of developing AD [40]. However, there are other factors, such as sex-
specific genetic and hormonal factors, which can contribute to variance in clinical efficacy 
[41]. Moreover, lifestyle choices such as smoking, excessive alcohol consumption, poor diet 
and resulting health conditions (obesity, type-2 diabetes, and cardiovascular disease) can 
have varied impacts on dementia risk, depending on sex [42]. For this analysis, age was 
subdivided into ‘young elderly’ (aged 65-74) and ‘older elderly’ (aged 75 years or older) [43]. 
This division accounts for the sharp rise in dementia cases over the age of 75 [5] – 15% of 
those with Alzheimer’s are aged 65–75, while 44% are aged 75–85 [2]. VOC analysis indicates 
that acetone, 2-propanol and 2-butanonecontributed significantly to the efficacy of our 
analysis for AD vs controls. These compounds are generally associated with normal breath 
[44]. Similarly, changes in other common breath markers, such as 2-propanol, hexanal, 
heptanal and 1-butanol, contributed to separation in AD vs MCI and MCI vs control tests. This 
suggests that AD-related changes in breath have a subtle impact on overall breath content. 
Changes in acetone are of particular interest. Early stages of AD are associated with region-
specific declines in brain glucose metabolism [45]. This can be supplemented by ketone 
bodies, including acetoacetate, β-hydroxybutyrate and acetone. These are usually produced 
from fat stores when glucose is unavailable, e.g. during prolonged fasting or when subscribing 
to a ketogenic diet, which could lead to increased levels of acetone in the exhaled breath in 
AD patients. AD patients often suffer loss of appetite, with nearly half of mild-AD subjects 
reporting appetite changes [46]. The changes observed in exhaled acetone in this study could 
be related to this phenomenon. To the best of our knowledge, there is currently no known 
link between 1-butanol and metabolic pathways relating to AD or other NDDs. However, 
concurrence in the identification of this VOC in this study and Bach et al. [20] suggested that 
there may be a connection, which is worthy of further investigating. Analysis of possible 
confounding factors indicate that gender, smoking, age and alcohol consumption have 
insignificant influence on breath content, in this study. Of these factors, alcohol seems to have 
the most influence, with an AUC of around 0.60. However, this factor is not significant enough 
to create two distinct groups or undermine the AD-related analysis. A limitation of this study 
is that the possible effects of medications and co-diseases/conditions were not considered in 
the confounding factor analysis. However, it should be noted that medication is inherently 
difficult to adequately assess, since it is not necessarily possible to discern between 
pharmacokinetic effects and underlying disease. Moreover, in this case, there are a large 
number of factors to consider; 65 co-diseases and 73 medications for MCI subjects and 57 co-
diseases and 55 medications reported in the AD cohort – many of which are age-related 
instead of disease-related. The possible effects caused by the most frequently listed co-
diseases/conditions and medications are therefore likely to be reduced, as they are similarly 
represented in both MCI and AD groups. Another drawback is that the medication and co-
diseases/conditions of controls are not available; however, this group is likely to be associated 
with similar age-related medication and co-diseases/conditions as the MCI and AD groups. 
While there is a general consensus on clinical diagnostic criteria for patients with AD and MCI 
due to AD, correct clinical diagnosis of AD is reported to be around 77% [47] – especially since 
other forms of dementia may be misdiagnosed as AD, and vice versa [48]. Misdiagnosis 
hinders research efforts and clinical trials since incorrect patient groups can obfuscate 
important findings. However, the results from this study suggest that the patient assessments 
by Author S.P. were fairly accurate with regard to clinical diagnosis of recruited subjects. 
Further work from this study should involve recruiting a larger sample size to validate results, 
reduce the potential effects of incorrect patient groups, and enhance the performance of the 
applied method (e.g. to increase sensitivity and specificity). In future, we also hope to go 
beyond distinguishing between diagnostic groups by developing an approach which could be 
used for personalised disease detection. 
 
 
5 Conclusions 
Results from this pilot study confirm the potential utility of analysing breath VOCs to 
distinguish between MCI, AD and controls. Though this was a simple study, with relatively 
clean/well defined groups, our approach was consistently able to separate between 
diagnostic groups [AUC±95%, sensitivity, specificity], controls vs MCI: [0.77 (0.64 – 
0.9), 0.68, 0.8], controls vs AD: [0.83(0.72 – 0.94), 0.6, 0.96], and MCI vs AD: [0.70 (0.55 
– 0.85), 0.6, 0.84].Analysis of possible confounding factors suggest that gender, age, 
smoking habits and alcohol consumption had insignificant influence on breath content. VOC 
analysis indicates that six compounds, tentatively identified as acetone,2-propanol, 2-
butanone, hexanal, heptanal and 1-butanol play a crucial role in distinguishing between 
diagnostic groups. The GC-IMS analysis technique was shown to be suitable for non-
invasive sampling of elderly subjects and demonstrates potential as a fast, high-throughput, 
real-time diagnostic tool for AD in a point-of-care clinical setting. 
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